Skip to main content

ECRAID-Prime

European Clinical Research Alliance on Infectious Diseases: Primary care adaptive platform trial for pandemics and epidemics.

  
explore

COVID-19 therapeutics in primary care

European citizens affected by COVID-19 have been well-served by landmark clinical trials in hospitals that have found treatments that save many lives. However, there are fewer opportunities for people in the community to contribute to the urgent mission of finding treatments that speed recovery, and reduce the need for hospital admission in the first place. Desperately needed, evidence-based therapeutics for use in primary care have the potential for considerable reach and impact on individual suffering and functioning, as well as on the sustainability of health services.

ECRAID-Prime, a European Adaptive Platform Trial (APT) of COVID-19 therapeutics in primary care will build on many years of EU investment in infrastructure for primary care trials and a mature primary care research network that has pioneered novel, efficient, platform clinical trial designs.

  

Project Lead Chris Butler says that “despite vaccination and emerging evidence for the effectiveness of oral anti-viral agents and novel monoclonal antibodies, many people continue to be infected by the SARS-CoV-2 virus, and require hospital admission. That makes finding new and cost-effective treatments for use in the community a top priority. ECRAID-Prime will select and evaluate novel approaches for community treatment of COVID-19. There are many exciting approaches that require further evaluation, and this novel international platform study will be a huge resource generating the high-quality evidence needed on proof of principle and efficacy.”

ECRAID-Prime is a multi-country collaboration that builds on several other European Union funded projects and strong clinical and academic relationships, and therefore sits on solid foundations. We look forward to working with a range of partners to implement unique earlier phase research for the community treatment of COVID-19.

Along with EU-SolidAct and REMAP-CAP, ECRAID-Prime is part of JAAM, the Joint Access Advisory Mechanism that provides a gateway to COVID-19 adaptive platform trials taking place in Europe. JAAM assesses requests from investigators and industry who are looking to test their compounds in one or more of these trials.

ECRAID-Prime is funded by the European Union. Views and opinions expressed are however those of the author(s) only and do not necessarily reflect those of the European Union. Neither the European Union nor the granting authority can be held responsible for them.